List bc paywall: Milvexian, Inclacumab, Troriluzole, Anselamimab, Simufilam, Astegolimab, Repibresib, Itepekimab, Monlunabant, Setrusumab
Trends: Gene and cell therapy continue to struggle in humans, and a lot of late stage failures in big expensive phase 2 and 3 trials that fail to meet their primary endpoints, especially in tricky complex diseases- CNS/Neuro, Immunology/Inflammation.
I'd add Navacaprant, Rocket Pharmaceuticals gene therapy, Novo Nordisk semaglutide for Alzheimers and Sarepta's Elevidys gene therapy to the list of biggest failed trials last year.
List bc paywall: Milvexian, Inclacumab, Troriluzole, Anselamimab, Simufilam, Astegolimab, Repibresib, Itepekimab, Monlunabant, Setrusumab
Trends: Gene and cell therapy continue to struggle in humans, and a lot of late stage failures in big expensive phase 2 and 3 trials that fail to meet their primary endpoints, especially in tricky complex diseases- CNS/Neuro, Immunology/Inflammation.
I'd add Navacaprant, Rocket Pharmaceuticals gene therapy, Novo Nordisk semaglutide for Alzheimers and Sarepta's Elevidys gene therapy to the list of biggest failed trials last year.